Myriad Genetics 8-K
PositiveEarningsNew guidance
Hereditary cancer and mental health test volumes rose as prenatal fell; new FY2026 margin guidance incorporates product-launch impacts.
Filed 2026-01-12 08:31 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Preliminary Q4 and FY2025 results with initiated FY2026 guidance. Myriad expects Q4 2025 revenue of $207M–$209M and FY2025 revenue of $822M–$824M. The results are unaudited and may change during year-end close and audit; actual results are expected in February 2026.
Key Figures
| Metric | Period | Preliminary result | Prior period | Y/Y |
|---|---|---|---|---|
| Revenue | Q4 2025 | $207M–$209M | — | — |
| Revenue | FY2025 | $822M–$824M | — | — |
- FY2025 total test volume: ≈1.5M, up 1%; hereditary cancer volume rose ≈7%, mental health rose ≈6%, and prenatal health fell ≈4%.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Revenue | FY2026 | $860M–$880M; midpoint ≈6% above the preliminary FY2025 revenue midpoint | — | Initiated |
| Adjusted gross margin, non-GAAP | FY2026 | 68%–69% | — | Initiated |
| Adjusted EBITDA, non-GAAP | FY2026 | $37M–$49M; midpoint expected to grow ≈43% vs the midpoint of prior FY2025 guidance | — | Initiated |
Investor Takeaways
- February 2026 actual FY2025 results will confirm whether preliminary revenue holds after year-end close and audit.
- FY2026 revenue, adjusted gross margin and adjusted EBITDA results will show progress against the new guidance; the company says the margin range incorporates anticipated new-product-launch impacts.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3